Brokerage firm Janney Capital Upgrades its rating on PerkinElmer(PKI). The shares have been rated Buy. Previously, the analysts had a Neutral rating on the shares. The rating by the stock financial advisor at Janney Capital was issued on Mar 27, 2017 in a research report to their Investors and Clients.
In a different note, On Feb 3, 2017, Bank of America said it Downgrades its rating on PerkinElmer. The shares have been rated ‘Underperform’ by the firm. Deutsche Bank said it Initiates Coverage On PerkinElmer, according to a research note issued on Jan 18, 2017. In the research note, the firm Announces the price-target to $55 per share. The shares have been rated ‘Hold’ by the firm.
PerkinElmer (PKI) shares turned negative on Fridays trading session with the shares closing down -0.07 points or -0.12% at a volume of 5,98,169. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $58.08. The peak price level was also seen at $58.08 while the days lowest was $57.38. Finally the shares closed at $57.52. The 52-week high of the shares is $58.08 while the 52-week low is $45.35. According to the latest information available, the market cap of the company is $6,315 M.
PerkinElmer(PKI) last announced its earnings results on Feb 2, 2017 for Fiscal Year 2016 and Q4.Company reported revenue of $566.770M. Analysts had an estimated revenue of $612.170M. Earnings per share were $0.83. Analysts had estimated an EPS of $0.86.
Several Insider Transactions has been reported to the SEC. On Mar 21, 2017, Andrew Okun (officer ) sold 3,000 shares at $57.27 per share price.Also, On Mar 15, 2017, Frank Anders Wilson (officer ) sold 37,535 shares at $55.45 per share price.On Mar 15, 2017, Joel S Goldberg (officer ) sold 30,710 shares at $55.45 per share price, according to the Form-4 filing with the securities and exchange commission.
PerkinElmer Inc. is a provider of products services and solutions to the diagnostics research environmental industrial and laboratory services markets. The Company operates its business in two segments: Human Health and Environmental Health. The Companys Human Health segment concentrates on developing diagnostics tools and applications to help detect diseases earlier and more accurately and to accelerate the discovery and development of new therapies. The Companys Environmental Health segment provides products services and solutions to facilitate the creation of safer food and consumer products more secure surroundings and efficient energy resources. The Company markets its products and services in more than 150 countries.